Abbvie Inc (ABBV)

$218.63 +3.23 (1.50%)
Market Cap 376.54B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 21.17
Forward PE 15.08
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 5,115,714
Avg Vol 6,729,662
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 63%
Beta 0.32
Analysts Strong Sell
Price Target $250.90

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Mike22332233
Mike22332233 May. 28 at 8:17 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! .. From here, SLS could return 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing & largest holding in $1.4 Mil portfolio !! .. ALSO, tomorrow I expect the twice delayed TO for $LSTA at $5.00 plus a CVR for another future possible $1.00, to move forward, and from current $3.14 price, to give me a +59% return ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I post my Special Situation Stocks that have potential for FAST & HUGE profits ... which I always plow back into more $SLS !!!
2 · Reply
Petersen73
Petersen73 May. 28 at 7:58 PM
$ABBV $CING $SCHW $SLS
0 · Reply
Taajom
Taajom May. 28 at 7:50 PM
$SLS 🚀 🚀 🚀 $ABBV $CING $SCHW https://truthsandnews.com/markets/sls-stock-analysis-may-28-2026-hitting-52-week-highs-ahead-of-event-80-regal-data
0 · Reply
Loudermilk64
Loudermilk64 May. 28 at 7:38 PM
$ABBV Keeps getting knocked down from around here.
0 · Reply
Tumblewood
Tumblewood May. 28 at 6:12 PM
$ABBV needs to buy $SLS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 28 at 6:09 PM
$SLS $ABBV review the historical pricing, $ABVX was scraping around $5 and change in the days ahead of releasing its Phase 3 Trial Results, the Share price had risen to $10 Per Share - the Day the PR HIT. - INSTANT T1 TRADING HALT and a GAP UP +600% - Share Price OPENED at $60 --- from $10 to $60 +600% in an Instant and the Share Price continued to Climb to a HIGH of $148 per share From $5 and Change to $148 - a Market Cap of $12.9B ... BILLY all Based on the Value of a P3 Trial Result. SOMETHING VERY SIMILAR BUT BIGGER IS ABOUT TO HAPPEN HERE. This is why we are now seeing the fud.
0 · Reply
HboFam
HboFam May. 28 at 6:04 PM
$SLS $ABBV $IBRX Angelos ”recent multi-center study evaluating real-world practice data for the highly active alternating regimen pioneered at MD Anderson Cancer Center (Kadia et al.) in older, high-risk Acute Myeloid Leukemia (AML) patients reveals a profound paradox in modern oncology: - High-intensity innovation works in community settings. 63% of untreated elderly patients (median age 74) achieved a composite complete remission (CRc). Modern triplets are successfully expanding the pool of patients achieving CR1 and CR2. - Despite being touted as a "bridge to transplant," only 15% of these patients actually made it to an allogeneic stem cell transplant. For the remaining 85% who are too frail or older, a steep "therapeutic cliff" remains. Without a transplant, their median overall survival was just 8 months, cut short by cumulative toxicities and eventual resistance to continuous chemotherapy backbones.”
0 · Reply
Loudermilk64
Loudermilk64 May. 28 at 5:28 PM
$ABBV Needs another Pandemic to go higher?
0 · Reply
nlrmandate
nlrmandate May. 28 at 4:57 PM
$VKTX @Wal187 why would I be worried about Viking based on LLYS successes? Although the main differentiator with Viking is same peptide SQ and PO (for maintenance), the TRUE differentiator is that Viking is the only clinical biotech with the chops to challenge $LLY (and it has most advanced pipeline). Thus, I applaud LLYs success, for that success is exactly what will spur $ABBV or $NVO to buy VKTX to compete with LLY. Long and insanely
1 · Reply
Loudermilk64
Loudermilk64 May. 28 at 4:27 PM
$ABBV Making another run at the HOD?
0 · Reply
Latest News on ABBV
AbbVie announces FDA approval of DECNUPAZ

2026-05-27T22:30:12.000Z - 23 hours ago

AbbVie announces FDA approval of DECNUPAZ

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 23 hours ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 1 day ago

US FDA approves AbbVie's rare blood cancer drug

FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm

2026-05-27T19:25:11.000Z - 1 day ago

FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm

AbbVie reports positive CHMP opinion for Maviret

2026-05-22T12:12:15.000Z - 6 days ago

AbbVie reports positive CHMP opinion for Maviret

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 6 days ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 6 days ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

2026-05-21T20:19:37.000Z - 7 days ago

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 7 days ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-15T12:51:42.000Z - 13 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

2026-05-14T20:15:24.000Z - 14 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

AbbVie price target raised to $298 from $294 at Piper Sandler

2026-05-14T11:07:12.000Z - 14 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 15 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

May 9, 2026, 10:08 AM EDT - 19 days ago

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 20 days ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 22 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

2026-05-05T12:32:52.000Z - 23 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 23 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 24 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

May 2, 2026, 8:45 AM EDT - 26 days ago

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AZN GSK

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 27 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 27 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 4 weeks ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T18:00:46.000Z - 4 weeks ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 4 weeks ago

AbbVie price target raised to $265 from $262 at Canaccord

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 4 weeks ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 4 weeks ago

AbbVie upgraded to Buy at BofA on durable growth

AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 4 weeks ago

AbbVie upgraded to Buy from Neutral at BofA

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

Apr 29, 2026, 2:50 PM EDT - 4 weeks ago

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:41:09.000Z - 4 weeks ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:58.000Z - 4 weeks ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 4 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 4 weeks ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 4 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 4 weeks ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 4 weeks ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 5 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 5 weeks ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 5 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 5 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 5 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 6 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 6 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 6 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

Apr 9, 2026, 2:00 PM EDT - 7 weeks ago

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

AMCR CVX

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 7 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 7 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 7 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 7 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 7 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 2 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 2 months ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 2 months ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 2 months ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 2 months ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 2 months ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Mar 6, 2026, 8:26 AM EST - 2 months ago

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

GILD V

Mike22332233
Mike22332233 May. 28 at 8:17 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! .. From here, SLS could return 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing & largest holding in $1.4 Mil portfolio !! .. ALSO, tomorrow I expect the twice delayed TO for $LSTA at $5.00 plus a CVR for another future possible $1.00, to move forward, and from current $3.14 price, to give me a +59% return ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I post my Special Situation Stocks that have potential for FAST & HUGE profits ... which I always plow back into more $SLS !!!
2 · Reply
Petersen73
Petersen73 May. 28 at 7:58 PM
$ABBV $CING $SCHW $SLS
0 · Reply
Taajom
Taajom May. 28 at 7:50 PM
$SLS 🚀 🚀 🚀 $ABBV $CING $SCHW https://truthsandnews.com/markets/sls-stock-analysis-may-28-2026-hitting-52-week-highs-ahead-of-event-80-regal-data
0 · Reply
Loudermilk64
Loudermilk64 May. 28 at 7:38 PM
$ABBV Keeps getting knocked down from around here.
0 · Reply
Tumblewood
Tumblewood May. 28 at 6:12 PM
$ABBV needs to buy $SLS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 28 at 6:09 PM
$SLS $ABBV review the historical pricing, $ABVX was scraping around $5 and change in the days ahead of releasing its Phase 3 Trial Results, the Share price had risen to $10 Per Share - the Day the PR HIT. - INSTANT T1 TRADING HALT and a GAP UP +600% - Share Price OPENED at $60 --- from $10 to $60 +600% in an Instant and the Share Price continued to Climb to a HIGH of $148 per share From $5 and Change to $148 - a Market Cap of $12.9B ... BILLY all Based on the Value of a P3 Trial Result. SOMETHING VERY SIMILAR BUT BIGGER IS ABOUT TO HAPPEN HERE. This is why we are now seeing the fud.
0 · Reply
HboFam
HboFam May. 28 at 6:04 PM
$SLS $ABBV $IBRX Angelos ”recent multi-center study evaluating real-world practice data for the highly active alternating regimen pioneered at MD Anderson Cancer Center (Kadia et al.) in older, high-risk Acute Myeloid Leukemia (AML) patients reveals a profound paradox in modern oncology: - High-intensity innovation works in community settings. 63% of untreated elderly patients (median age 74) achieved a composite complete remission (CRc). Modern triplets are successfully expanding the pool of patients achieving CR1 and CR2. - Despite being touted as a "bridge to transplant," only 15% of these patients actually made it to an allogeneic stem cell transplant. For the remaining 85% who are too frail or older, a steep "therapeutic cliff" remains. Without a transplant, their median overall survival was just 8 months, cut short by cumulative toxicities and eventual resistance to continuous chemotherapy backbones.”
0 · Reply
Loudermilk64
Loudermilk64 May. 28 at 5:28 PM
$ABBV Needs another Pandemic to go higher?
0 · Reply
nlrmandate
nlrmandate May. 28 at 4:57 PM
$VKTX @Wal187 why would I be worried about Viking based on LLYS successes? Although the main differentiator with Viking is same peptide SQ and PO (for maintenance), the TRUE differentiator is that Viking is the only clinical biotech with the chops to challenge $LLY (and it has most advanced pipeline). Thus, I applaud LLYs success, for that success is exactly what will spur $ABBV or $NVO to buy VKTX to compete with LLY. Long and insanely
1 · Reply
Loudermilk64
Loudermilk64 May. 28 at 4:27 PM
$ABBV Making another run at the HOD?
0 · Reply
TechridyStocks
TechridyStocks May. 28 at 2:40 PM
Inv hs $ABBV
0 · Reply
maikl_211
maikl_211 May. 28 at 2:21 PM
$ABBV $MU $GE $PG $CVX
0 · Reply
Mike22332233
Mike22332233 May. 28 at 11:59 AM
$SLS From here, $SLS could return an additional 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing !!! ... the opening BO Offer will be placed at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... This is the largest position in an almost $1.4 mil portfolio … Again, this is the single best asymmetrical investment I have found in over 40 years of investing !!!! ... The play here is simple …. Buy as much as you can after doing your DD … HOLD until BO (ignore everything from now till BO) !!!! … AND after first offer is made … Look for a bidding war !!!!! … Best of luck to all !!! … And, remember to PLEASE always give back something to medical research ... If you agree ...... LIKE & FOLLOW me 👉 @Mike22332233 for all latest info and DD -- and maybe find THE NEXT SLS !!!
3 · Reply
Mike22332233
Mike22332233 May. 28 at 11:51 AM
$SLS I have been one of the very few -- if not the only one -- that has CONSISTENTLY been saying: ... When the 80th event occurs, you will find that all 63 out of 63 BAT patients have passed ... And that 46 of the 63 GPS patients still live ... (that is my most logical conclusion based on all the data out over time) ... And, the HR value will be GROUND BREAKING at 0.27-0.33 and a new SoC !!!! .... And, BO will involve a bidding war between 2 -- and maybe even 3 -- of the following: $MRK, $PFE, and $ABBV !!! ... If you agree ...... LIKE & FOLLOW me 👉 @Mike22332233 for all latest info and DD
1 · Reply
HboFam
HboFam May. 28 at 5:56 AM
$SLS $ABBV $IBRX Angelos ”recent multi-center study evaluating real-world practice data for the highly active alternating regimen pioneered at MD Anderson Cancer Center (Kadia et al.) in older, high-risk Acute Myeloid Leukemia (AML) patients reveals a profound paradox in modern oncology: - High-intensity innovation works in community settings. 63% of untreated elderly patients (median age 74) achieved a composite complete remission (CRc). Modern triplets are successfully expanding the pool of patients achieving CR1 and CR2. - Despite being touted as a "bridge to transplant," only 15% of these patients actually made it to an allogeneic stem cell transplant. For the remaining 85% who are too frail or older, a steep "therapeutic cliff" remains. Without a transplant, their median overall survival was just 8 months, cut short by cumulative toxicities and eventual resistance to continuous chemotherapy backbones.”
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 28 at 1:21 AM
$SLS $ABBV $IBRX
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 11:22 PM
$SLS $ABBV $IBRX 3 Dr/s Who Treat Actual Phase 3 Trial patients: " Survival on BAT is dismal, just 6-8 months" "extremely poor on the order of 5-7 months" " I Strongly believe Gps will reach the primary endpoint "/
3 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 10:51 PM
$SLS market value increased 1,200% since the IDMC UNBLINDED ACTUAL PHASE 3 MOS AND IR DATA from the Interim Analysis Actual Phase 3 Survival and Immune Response Data - that TOLD Smart Money Paying Attention - GPS is 100% For Sure Golden. - 167 Institutional Funds Invested - Up from Just 39 While We are seeing near MIRACULOUS Extended Survival Among ALL POOLED P3 Patients in the REGAL trial for SECOND REMISSION MAINTENANCE (CR2) - Aza+VEN / BAT Best Available Treatment for Control Arm Patients Recently FAILED 3 Large Phase 3 Trials conducted by $ABBV VIALE-M - AML First Remission Maintenance Trial FAILED VIALE-T - AML Post Transplant Maintenance Trial FAILED VERONA - MDS/High Risk AML Precursor Trial FAILED. $IBRX is DEAD MONEY vs What SLS will Be Doing. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
Mike22332233
Mike22332233 May. 27 at 9:52 PM
$SLS From here, $SLS could return an additional 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing !!! ... the opening BO Offer will be placed at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... This is the largest position in an almost $1.4 mil portfolio … Again, this is the single best asymmetrical investment I have found in over 40 years of investing !!!! ... The play here is simple …. Buy as much as you can after doing your DD … HOLD until BO (ignore everything from now till BO) !!!! … AND after first offer is made … Look for a bidding war !!!!! … Best of luck to all !!! … And, remember to PLEASE always give back something to medical research ... If you agree ...... LIKE & FOLLOW me 👉 @Mike22332233 for all latest info and DD -- and maybe find THE NEXT SLS !!!
3 · Reply
Loudermilk64
Loudermilk64 May. 27 at 9:00 PM
$ABBV this stock always loses. What gains are they talking about?
0 · Reply
StocktwitsNews
StocktwitsNews May. 27 at 8:26 PM
ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug $ABBV https://stocktwits.com/news/equity/markets/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug/cZggZYAReru
0 · Reply
SwingTraderPro1
SwingTraderPro1 May. 27 at 8:08 PM
BREAKING: $ABBV just secured FDA approval for pivekimab sunirine-PVZY targeting blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and highly aggressive blood cancer. This is not just another label expansion,this is AbbVie deepening its footprint in ultra-orphan hematology, where pricing power and unmet need are both extreme. Traders should note: rare disease approvals often translate into high-margin, low-competition revenue streams over time. Long-term pipeline strength just got another boost. Watch how the market digests this—biotech catalysts like this can quietly re-rate big pharma over time. $ABBV in play.
0 · Reply